A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease that lack of effective therapeutic drugs. K-001 is an oral antitumor drug made from active ingredients of marine microorganisms. The current study aimed to evaluate safety and antitumor activity of K-001 in patients with...

Full description

Bibliographic Details
Main Authors: Jiujie Cui, Haiyan Yang, Jue Liu, Donghui Chen, Jiong Hu, Haiyan Zhang, Yu Wang, Ting Han, Tiebo Mao, Feng Jiao, Ewelina Biskup, Yaotian Pan, Min Liu, Liwei Wang
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Cancer
Subjects:
Pancreatic ductal adenocarcinoma
Phase I study
Safety
K-001
Clinical trial
Online Access:https://doi.org/10.1186/s12885-021-08375-6

Similar Items

Similar Items